| Mar 23, 2020

Substance Use Disorder (SUD) and Mental Health

If you have materials you are willing to share with other states through this page, or if there are topics of particular concern that you would like addressed, please contact SHVS.

STATE HEALTH AND VALUE STRATEGIES RESOURCES

SHVS/Manatt Health. State Medicaid and CHIP Strategies to Respond to the COVID-19 Public Health Crisis  This expert perspective, written by experts at Manatt Health, discusses strategies state Medicaid and CHIP agencies can pursue as part of their response to COVID-19.

SHVS/Manatt Health. Responding to COVID-19: State Strategies for Medicaid and Commercial Health Insurance Oversight  Webinar recording and slide deck from webinar hosted on March 18, 2020.

——————————————————–

OTHER RESOURCES

STATE TEMPLATES AND TOOLKITS

CMS. 1115 Application Process  This page includes guidance and a template for COVID-19 1115 waiver demonstrations. 

——————————————————-

FEDERAL STATUTE AND GUIDANCE

CMS/CMCS. COVID-19 Frequently Asked Questions (FAQs) for State Medicaid and Children’s Health Insurance Program (CHIP) Agencies  These updated FAQs for state Medicaid and CHIP agencies address available resources for emergency preparedness and response efforts, and flexibilities related to eligibility and enrollment, benefits, cost-sharing, financing, and workforce.

Substance Abuse and Mental health Services Administration (SAMHSA).  Considerations for Crisis Centers and Clinicians in Managing the Treatment of Alcohol or Benzodiazepine Withdrawal during the COVID-19 Epidemic

Substance Abuse and Mental health Services Administration (SAMHSA).  Considerations for the Care and Treatment of Mental and Substance Use Disorders in the COVID-19 Epidemic  This guidance advises outpatient providers to utilize telehealth, whenever possible, reschedule non-urgent appointments, reach out to high risk patients for COVID-19, eliminate cancellation/no show fees.

Substance Abuse and Mental health Services Administration (SAMHSA).  Frequently Asked Questions (FAQs) Related to COVID-19 for SAMHSA Grant Recipients  This FAQ addresses general questions associated with award and management of SAMHSA discretionary grants that may arise in relation to COVID-19.

Substance Abuse and Mental health Services Administration (SAMHSA).  Interim Considerations for State Psychiatric Hospitals  This guidance details infection control and social distancing recommendations for state psychiatric hospitals.

Substance Abuse and Mental health Services Administration (SAMHSA).  OTP Guidance for Patients Quarantined at Home with the Coronavirus  This guidance advises that Opioid Treatment Programs on providing medications to patients who are quarantined with COVID-19.

Substance Abuse and Mental health Services Administration (SAMHSA).  COVID-19 Public Health Emergency Response and 42 CFR Part 2 Guidance  This guidance clarifies that medical emergency exception to Part 2 applies during COVID-19.

Substance Abuse and Mental health Services Administration (SAMHSA).  Opioid Treatment Program (OTP) Guidance

Drug Enforcement Administration (DEA). Exception to Regulations Emergency Oral CII Prescription  This guidance allows prescribers and practitoners to issue time limited prescriptions of schedule II drugs via oral communication (e.g., telephone) under limited circumstances.

Drug Enforcement Administration (DEA).  Exception to Separate Registration Requirements Across State Lines  This guidance allows practitioners to dispense schedule II-IV drugs (including methadone, buprenorphine and opioids) not only in their home states but also in states with which their home stateshave reciprocity. 

Drug Enforcement Administration (DEA).  Exemption Allowing Alternate Delivery Methods for OTPs  This guidance allows OTPs to make “door stop” deliveries for medications for opioid use disorder in a lock-box for patients under quarantine.

Drug Enforcement Administration (DEA).  Registrant Guidance on Controlled Substance Prescription Refills  This guidance allows pharmacists to dispense early refills of prescriptions for schedule II-IV drugs (including methadone, buprenorphine and opioids) consistent with state law and regulation.

Substance Abuse and Mental health Services Administration (SAMHSA). FAQs: Provision of Methadone and Buprenorphine for the Treatment of Opioid Use Disorder in the COVID-19 Emergenc This FAQ clarifies that OTPs may initiate new patients on buprenorphine via telehealth and without an in-person visit, but maintains the face to face requirement for initiation with methadone.

——————————————————-

ANALYSIS

Manatt Health. Summary of Healthcare Provisions of COVID-19 Stimulus Package #3 (CARES Act)

Foundation for Opioid Response Efforts (FORE), National Academy for State Health Policy (NASHP), Manatt Health Federal and State Policy Levers to Maintain Access to Medications for Opioid Use Disorder During the COVID-19 Pandemic

——————————————————-

STATE EXAMPLES AND MODELS

California.  DHCS COVID‑19 Response  CA developed a robust, centralized COVID-19 resource page that provides guidance related to providers, HCBS, and federal requests/waivers.

Pennsylvania.  Wolf Administration Urges Drug and Alcohol Treatment Providers to Review Community Plans